$ABCL
AbCellera Biologics Inc.
CIK:0001703057|SEC Filings
Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Revenue: | ||||||
| Total revenue | $ 4,050 | $ 17,084 | $ 12,362 | $ 21,320 | ||
| Operating expenses: | ||||||
| Research and development | [1] | 45,987 | 39,213 | 92,649 | 81,711 | |
| Sales, general, and administrative | [1] | 13,850 | 21,986 | 26,185 | 41,054 | |
| Depreciation and amortization | 6,990 | 5,470 | 13,828 | 10,801 | ||
| Total operating expenses | 66,827 | 66,669 | 132,662 | 133,566 | ||
| Loss from operations | (62,777) | (49,585) | (120,300) | (112,246) | ||
| Other (income) expense: | ||||||
| Interest and other | 42 | (9,549) | (3,606) | (15,073) | ||
| Grants and incentives | (3,854) | (3,692) | (8,193) | (7,845) | ||
| Total other income | (3,812) | (13,241) | (11,799) | (22,918) | ||
| Loss before income tax | (58,965) | (36,344) | (108,501) | (89,328) | ||
| Income tax recovery | (3,538) | (1,617) | (9,909) | (8,980) | ||
| Net loss | (55,427) | (34,727) | (98,592) | (80,348) | ||
| Foreign currency translation adjustment | (733) | 4,341 | 1,082 | 1,721 | ||
| Comprehensive loss | $ (56,160) | $ (30,386) | $ (97,510) | $ (78,627) | ||
| Net loss per share | ||||||
| Basic (in dollars per share) | $ (0.18) | $ (0.12) | $ (0.32) | $ (0.27) | ||
| Diluted (in dollars per share) | $ (0.18) | $ (0.12) | $ (0.32) | $ (0.27) | ||
| Weighted-average common shares outstanding | ||||||
| Basic (in shares) | 305,557,294 | 298,508,601 | 304,329,623 | 298,105,760 | ||
| Diluted (in shares) | 305,557,294 | 298,508,601 | 304,329,623 | 298,105,760 | ||
| Research fees | ||||||
| Revenue: | ||||||
| Total revenue | $ 3,901 | $ 6,639 | $ 12,021 | $ 10,707 | ||
| Licensing and royalty revenue | ||||||
| Revenue: | ||||||
| Total revenue | $ 149 | $ 10,445 | $ 341 | $ 10,613 | ||
| ||||||